Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo/Ranbaxy deal is binding, companies stress

This article was originally published in Scrip

Executive Summary

Apparently tiring of media and investor speculation about possible counter-bids and potential back-tracking, Daiichi Sankyoand Ranbaxyhave issued a statement stressing that their merger agreement is "binding and final", subject to requisite regulatory approvals. Both firms and Ranbaxy's controlling Singh family "remain committed to the transaction and…stand by the deal and confirm that the terms of the deal remain unchanged", the statement said. It added that the share transactions had been approved unanimously by both boards, and now also by shareholders, which "clears the decks for the deal to proceed as planned".


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts